Chen Jia, Peng Wenxuan, Yang Wen, You Zhipeng, Zou Yuling
The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Province Key Laboratory of Ophthalmology and Vision Sciences, Jiangxi Clinical Research Center for Ophthalmic Disease, Jiangxi Provincial Key Laboratory of Vitreoretinal Diseases for Health, Jiangxi Province, Nanchang, 330006, China.
The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, Jiangxi Province Key Laboratory of Ophthalmology and Vision Sciences, Jiangxi Clinical Research Center for Ophthalmic Disease, Jiangxi Provincial Key Laboratory of Vitreoretinal Diseases for Health, Jiangxi Province, Nanchang, 330006, China.
Exp Eye Res. 2025 Oct;259:110531. doi: 10.1016/j.exer.2025.110531. Epub 2025 Jul 21.
This study investigates ferroptosis in human retinal microvascular endothelial cells (HRMECs) under high-glucose conditions and explores the therapeutic potential of Berberine (BBR) in mitigating this process. Using Western blotting and RT-qPCR, we observed that prolonged high glucose (48 h) significantly downregulated GPX4 and FSP1 protein levels, reduced GPX4 mRNA expression, and elevated ACSL4 protein levels, indicative of ferroptosis induction. BBR intervention reversed these effects, upregulating Nrf2, HO-1, GPX4, and FSP1 while suppressing ACSL4. Mechanistically, BBR attenuated oxidative stress by reducing ROS, lipid peroxidation (MDA), and Fe accumulation, as demonstrated via fluorescence microscopy, GSH/MDA assays, and transmission electron microscopy, which revealed preserved mitochondrial integrity in BBR-treated cells. CCK-8 assays confirmed BBR's role in restoring HRMEC viability under high glucose. These findings highlight BBR's ability to inhibit ferroptosis through the Nrf2/HO-1/GPX4 pathway, offering novel insights into diabetic retinopathy (DR) pathogenesis and suggesting BBR as a promising therapeutic candidate to delay DR progression.
本研究调查了高糖条件下人视网膜微血管内皮细胞(HRMECs)中的铁死亡,并探索了黄连素(BBR)在减轻这一过程中的治疗潜力。通过蛋白质免疫印迹法和逆转录定量聚合酶链反应(RT-qPCR),我们观察到长时间高糖(48小时)显著下调了谷胱甘肽过氧化物酶4(GPX4)和铁死亡抑制蛋白1(FSP1)的蛋白水平,降低了GPX4信使核糖核酸(mRNA)表达,并升高了长链脂酰辅酶A合成酶4(ACSL4)的蛋白水平,表明诱导了铁死亡。BBR干预逆转了这些效应,上调了核因子E2相关因子2(Nrf2)、血红素加氧酶-1(HO-1)、GPX4和FSP1,同时抑制了ACSL4。从机制上讲,BBR通过减少活性氧(ROS)、脂质过氧化(丙二醛,MDA)和铁积累来减轻氧化应激,荧光显微镜、谷胱甘肽/丙二醛(GSH/MDA)检测和透射电子显微镜证实了这一点,透射电子显微镜显示BBR处理的细胞中线粒体完整性得以保留。细胞计数试剂盒-8(CCK-8)检测证实了BBR在恢复高糖条件下HRMEC活力中的作用。这些发现突出了BBR通过Nrf2/HO-1/GPX4途径抑制铁死亡的能力,为糖尿病视网膜病变(DR)的发病机制提供了新的见解,并表明BBR是延缓DR进展的有前景的治疗候选药物。